Prevenar 13™

BIOLOGICAL4 trials

Sponsors

MCM Vaccines B.V., Pfizer, Merck Sharp & Dohme LLC

Conditions

Bacterial InfectionsInfections, MeningococcalPneumococcal InfectionsVirus Diseases

Phase 3

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)

CompletedNCT01480258

MCM Vaccines B.V.Bacterial Infections, Virus Diseases

Start: 2011-11-23End: 2013-10-09Updated: 2019-04-02

Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine

CompletedNCT01939158

PfizerInfections, Meningococcal

Start: 2013-10-02End: 2019-12-05Updated: 2021-10-05

Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)

CompletedNCT04016714

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2019-08-28End: 2021-10-29Updated: 2023-05-06

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)

CompletedNCT04031846

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2019-09-04End: 2021-08-05Updated: 2023-07-28

Related Papers

A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).

2023-04-2520 citations

A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5 years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12-14-month-old children.

2023-01-063 citations

Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study.

2018-03-0213 citations

A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months.

2016-06-1828 citations